FDA PCAC July 23-24, 2026: Seven Peptides Under Review for Compounding Legalization

The July 23-24 PCAC Meeting: What Is Being Decided

The FDA's Pharmacy Compounding Advisory Committee will convene for a two-day public meeting on July 23 and 24, 2026, to discuss whether seven peptide bulk drug substances should be added to the 503A Bulks List, a designation that would make them legal for compounding pharmacies to prepare for individual patients with valid prescriptions.

The meeting agenda is divided across two days:

July 23: BPC-157 (body protection compound), KPV (a tripeptide fragment of alpha-MSH), TB-500 (thymosin beta-4 fragment), and MOTS-C (a mitochondrial peptide)

July 24: Emideltide (also known as delta sleep-inducing peptide, or DSIP), Semax (a synthetic ACTH fragment with nootropic properties), and Epitalon (a tetrapeptide with reported telomerase-activating effects)

These seven peptides were among the 12 substances that the FDA removed from Category 2 of the 503A bulks list in April 2026, a regulatory shift that effectively moved them from "prohibited" status to a state where PCAC evaluation became possible.

Regulatory Background: From Category 2 to PCAC Review

To understand the significance of the July meeting, it helps to trace the regulatory trajectory these peptides have traveled:

2023: FDA moved more than a dozen peptides, including BPC-157, TB-500, and others, to Category 2 of the 503A bulks list. This designation effectively prohibited compounding pharmacies from preparing these substances. The rationale was that insufficient evidence supported their safety, purity, and clinical utility when compounded.

2025-2026: Legal challenges from compounding industry associations and individual pharmacies contested FDA's Category 2 designations. Courts in several circuits scrutinized FDA's evidentiary standards for the categorical prohibition, and some legal scholars questioned whether the agency had adequately explained its determinations.

April 2026: HHS Secretary Kennedy announced removal of 12 peptides from Category 2, citing the MAHA (Make America Healthy Again) initiative's emphasis on access to health optimization compounds. The removal opened the path for PCAC to formally evaluate these substances.

July 23-24, 2026: PCAC convenes for the evaluation.

What the PCAC Actually Does

The Pharmacy Compounding Advisory Committee is an expert panel that provides FDA with non-binding recommendations on whether specific bulk drug substances meet the criteria for inclusion on the 503A Bulks List. For a substance to qualify, it must meet a three-part test:

1. There must be a clinical need that cannot be met by FDA-approved drugs
2. The substance must be used in compounding that is clinically appropriate for individual patients
3. The substance must not present safety concerns that would make use in compounding inappropriate

The committee's work involves reviewing submitted dossiers, hearing from public commenters (including both advocates and skeptics), and then voting on whether to recommend inclusion. For some substances, the committee may recommend conditional inclusion pending additional data or may recommend against inclusion.

The 503A vs. 503B Distinction: Critical for Industry Stakeholders

A persistent source of confusion in coverage of the July meeting is the conflation of 503A and 503B regulations. These are distinct legal frameworks with different implications:

503A compounding pharmacies operate under state pharmacy board oversight and compound medications for individual patients based on valid prescriptions. They cannot sell commercially or distribute across state lines without prescription. The PCAC's July meeting is exclusively about 503A eligibility.

503B outsourcing facilities are federally registered facilities that can manufacture compounds in larger quantities for distribution to healthcare facilities without patient-specific prescriptions. They operate under FDA cGMP-equivalent requirements. The July PCAC meeting does not address 503B inclusion, a separate regulatory process governs that category.

For healthcare providers who rely on peptide compounds purchased in bulk through outsourcing facilities, the July meeting's outcome does not directly affect current supply chains, even in a best-case scenario.

Rulemaking Timeline After PCAC

Even if the PCAC votes to recommend all seven peptides for 503A inclusion, a positive outcome by industry's standards, actual legalization for compounding requires additional steps:

1. FDA reviews committee recommendation and determines whether to initiate rulemaking (this determination is entirely FDA's discretion, not mandated by a positive PCAC vote)
2. Notice of proposed rulemaking is published in the Federal Register
3. Comment period runs, typically 60-90 days, during which industry, pharmacies, patient groups, and others can submit comments
4. FDA reviews comments and issues a final rule
5. Effective date passes before compounding is legally authorized

Under typical rulemaking timelines, this process takes 12-18 months from a positive committee vote. Expedited rulemaking is possible but has historically been reserved for genuine medical urgencies rather than access expansion initiatives.

The practical implication: compounding pharmacies should not interpret a positive July PCAC outcome as immediate permission to compound these substances. Legal counsel should be consulted before making any operational changes based on anticipated outcomes.

Peptide-by-Peptide Overview

BPC-157 (body protection compound) is a 15-amino acid peptide derived from a gastric protein. It has been studied for tissue healing, anti-inflammatory effects, and gastrointestinal protection. BPC-157 has a substantial preclinical literature but no completed phase II or III human clinical trials, which has been the primary basis for FDA's prior Category 2 designation.

TB-500 (thymosin beta-4 fragment) is a synthetic fragment of the naturally occurring protein thymosin beta-4. It has been investigated for wound healing and tissue repair. Like BPC-157, it has significant preclinical data but limited human trial evidence.

KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). It has demonstrated anti-inflammatory activity in preclinical models of inflammatory bowel disease. KPV is notably different from the other substances in having more mechanistic clarity about its target pathway.

MOTS-C is a mitochondria-derived peptide encoded within the mitochondrial genome. It has been studied for metabolic effects including glucose regulation and exercise performance. Research interest in MOTS-C has grown substantially since 2020 publications linking it to longevity pathways.

Emideltide (DSIP) is a nine-amino acid peptide originally isolated from rabbit cerebral fluid and studied for sleep-inducing and stress-modulating effects. It has a longer research history than many on the list.

Semax is a synthetic heptapeptide derived from ACTH(4-7) developed in Russia with a history of clinical use for cognitive function and neuroprotection. It has human clinical data from Russian trials, though these studies do not meet FDA's evidence standards for approved drugs.

Epitalon is a tetrapeptide (Ala-Glu-Asp-Gly) developed by the St. Petersburg Institute of Bioregulation and Gerontology. It has been studied for telomere length effects and longevity, again primarily in Russian literature.

Industry and Staffing Implications

The July meeting carries significant implications for the compounding pharmacy workforce and for peptide manufacturers supplying the compounding market:

Compounding pharmacies are watching the meeting closely to assess whether to maintain or expand peptide compounding capabilities. Positive outcomes could support hiring additional sterile compounding pharmacists and pharmacy technicians.

Peptide API suppliers to the compounding market, primarily Chinese API manufacturers, are calibrating inventory and capacity to anticipated demand scenarios following the meeting.

Legal and regulatory affairs professionals at healthcare companies are preparing compliance guidance for clinical staff regardless of meeting outcome, as the rulemaking process following the meeting will require ongoing monitoring.

Peptide research scientists are increasingly being asked to generate the clinical case reports, case series, and structured evidence summaries that can be submitted during the rulemaking comment period.

People Also Ask

What peptides are being reviewed at the FDA PCAC July 2026 meeting?

Seven peptides are under review: BPC-157, KPV, TB-500, and MOTS-C on July 23; and Emideltide (DSIP), Semax, and Epitalon on July 24. All are being evaluated for potential inclusion on the 503A Bulks List, which would allow compounding pharmacies to prepare them for individual patients with valid prescriptions.

Will the July 2026 PCAC meeting make peptides legal to compound?

Not immediately. A positive PCAC recommendation is non-binding and triggers formal notice-and-comment rulemaking that typically takes 12-18 months before becoming effective. Compounding pharmacies should not assume a positive vote authorizes immediate compounding.

What is the difference between 503A and 503B compounding?

503A compounding pharmacies compound for individual patients under state pharmacy board oversight. 503B outsourcing facilities are federally registered and can sell to healthcare facilities without patient-specific prescriptions, operating under FDA cGMP-equivalent standards. The July PCAC meeting addresses only 503A, outsourcing facilities are governed by a separate regulatory pathway.